CoVIg-19 PLASMA ALLIANCE

Working Together to Fight COVID-19 with Immunoglobulin (Ig) Therapy

How Your Plasma Could Lead to a Potential Treatment for COVID-19

When you donate your plasma, you become the essential first step in a journey to develop a potential treatment for COVID-19. Even though no one can predict the results of clinical trials, here is a quick overview of the intended plan.



1 PLASMA DONATION

Patients who have recovered from COVID-19 donate their plasma, which contains antibodies that could help the immune system fight the new coronavirus. The proteins found in plasma are the most important ingredients in making a potential treatment.

2 POTENTIAL TREATMENT MADE

Plasma collected from individual patients is pooled with plasma collected from other COVID-19 recovered plasma donors, processed, and concentrated into a liquid that contains a high level of antibodies. This plasma-derived therapy then needs to be tested to determine if it is safe and effective.

3 CLINICAL TRIALS BEGIN

Assuming sufficient plasma is collected, we are working to have the potential treatment in clinical trials and tested starting as early as June. The studies will look at whether the therapy could treat patients who are at risk for serious complications from COVID-19.

4 TRIAL RESULTS ANALYZED

Scientists will collect and carefully analyze all the data from the clinical trials to determine if the potential treatment is both safe and effective.

5 POTENTIAL TREATMENT APPROVED

If the US Food and Drug Administration (FDA) determines that the potential treatment is both safe and effective, it could be approved for specific uses in the United States related to treating patients who are at risk for serious complications from COVID-19.

6 MANUFACTURING

Assuming the potential treatment has been approved by the FDA, the Alliance intends to manufacture the therapy on a larger scale and distribute it to hospitals and other healthcare settings and healthcare providers.



7 POTENTIAL TREATMENT AVAILABLE

The treatment will then be ready for use. The timing for this depends on many factors, but if the work of the Alliance is successful, the potential treatment could be available this year, making it one of the earliest potential treatments.

The above infographic aims to provide potential plasma donors with a general overview of the biopharmaceutical development process so that they can better understand their role in it. It should not be construed as making any claims about any potential treatment, including the timeline for, and/or outcomes of, clinical trials and/or regulatory approval.